FindMyKOL

Joshua McFarlane, MD

Basic profile

Virginia Cancer Institute

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionRichmond, VA · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Joshua McFarlane is an Oncology physician affiliated with Virginia Cancer Institute. OpenAlex indexes 11 publications with 444 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
11publications

Publications indexed by OpenAlex. Counts exclude supporting files.

444citations

Citations across these publications.

7h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
57companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

57 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • AstraZeneca Pharmaceuticals LP
    Program year20259 payments
    $225
  • Novartis Pharmaceuticals Corporation
    Program year20258 payments
    $209
  • PFIZER INC.
    Program year20258 payments
    $177
All 128 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    62.6%
    PD-1 inhibitor45.9%
    Pembrolizumab60%Nivolumab40%
    Part B, office-administered≥27 patients
    CD38-directed Cytolytic Antibody12.1%
    Daratumumab100%
    Part B, office-administered≥13 patients

    + 11 more classes in this area

  • Musculoskeletal

    17%
    RANK Ligand Inhibitor16.8%
    Denosumab100%
    Part B, office-administered≥46 patients
    Bisphosphonate0.2%
    Zoledronic acid100%
    Part B, office-administered≥15 patients
  • Blood & clotting

    5.5%
    Erythropoiesis-stimulating Agent5.1%
    Epoetin alfa100%
    Part B, office-administered≥35 patients
    Factor Xa inhibitor0.3%
    Eliquis72%Xarelto28%
    Part D≥22 patients

    + 1 more class in this area

Where care is delivered (Part B)0.4% facility · 99.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”